<meta name="description" content="Hands-on tutorial for pharmacy GMP across US/EU/UK: USP //, UK NHS/MHRA aseptic services, EU national rules, facility and cleanroom controls, sterile/nonsterile compounding, hazardous drugs, EM, BUDs, documentation, and inspection readiness.”/>

GMP for Pharmacies & Hospital Pharmacy Settings — Step-by-Step, Inspection-Ready Guide

Pharmacy GMP marries clinical imperatives (timely patient doses) with manufacturing discipline (fit-for-purpose facilities, validated processes, documented evidence). In the US, practice is anchored by USP <795> (nonsterile compounding), USP <797> (sterile compounding), and USP <800> (hazardous drugs). In the EU/UK, hospital aseptic units operate to national rules (e.g., UK Guidance on the Safe and Secure Handling of Medicines, NHS QA standards, MHRA “Specials” framework) with GMP principles drawn from EU GMP and PIC/S. This pillar translates those expectations into a practical operating model for hospital and large community pharmacies.

1) Governance, Licensing & Scope of Service (US/EU/UK)

Define what you do—and under which rule set. Document the service portfolio (e.g., TPN, chemotherapy, syringe/infusion doses, ophthalmics, batch-made nonsteriles, ward reconstitution support). Map authorizations/licensure: US state board permits & USP adherence; in UK, hospital aseptic units under NHS QA oversight; for “Specials” manufacture, MHRA licensure applies. In the EU, compounding is overseen by national competent authorities and pharmacy inspectorates; where activity crosses into manufacturing for supply beyond patients in your care, full GMP requirements may apply.

• Acceptance: Written scope, responsibilities (Chief Pharmacist/QA Pharmacist/Production, QC/Release), and quality manual approved and trained; regulators/inspectorates correctly notified/licensed.
• Evidence: Quality manual, organogram & RACI, license/registration, service SOP index, change log.

2) Facility Design & HVAC: Cleanrooms, Segregation, Pressure Cascades

For sterile compounding, lay out an ISO-classified suite (e.g., ISO 7 buffer with ISO 5 primary engineering controls, segregated ante/transition, negative rooms for HD as required). Use pressure cascades to protect critical zones; for HD compounding under USP <800>, apply negative pressure in the containment secondary engineering control (C-SEC). Nonsterile rooms must be cleanable, well-lit, with dust control and dedicated hazardous-drug areas.

• Acceptance: Room classification verified at qualification; pressure/temperature/RH within defined ranges; smoke studies demonstrate unidirectional protection across the hood; surfaces intact & cleanable.
• Evidence: Qualification reports (as-built/at-rest/operational), differential pressure logs/alarms, smoke visualization videos, cleaning/disinfection logs with agent rotation.

3) Primary Engineering Controls (PEC) & Equipment Qualification

Qualify PECs (e.g., compounding aseptic isolators (CAIs), biological safety cabinets (BSCs), laminar airflow workbenches (LAFWs)) and critical equipment (balances, mixers, automated compounders, sterilizers). Calibrate balances and volumetric devices; qualify CV-critical automation (e.g., TPN compounders) with challenge recipes and gravimetric checks.

• Acceptance: PEC meets airflow/HEPA integrity, recovery, and leak criteria; alarms functional; equipment logbooks maintained; maintenance within schedule.
• Evidence: IQ/OQ/PQ packs, balancing/calibration certificates, HEPA/velocity/SMPS/particle tests, isolator pressure hold, automated compounder gravimetric validation.

4) Materials, Components & Inventory Controls

Approve suppliers and components (APIs, excipients, diluents, containers/closures, tubing). On receipt, quarantine until identity/visual checks pass; record lot numbers and expiry; implement FEFO. For HDs, store under negative pressure as required; segregate cytotoxic waste. For CSPs (compounded sterile preparations), control sterile water/diluents with lot traceability.

• Acceptance: Status labeling (quarantine/released/rejected), identity checks documented, sterile disposables kept bagged until transfer, chemical integrity managed (light/temp protection).
• Evidence: Goods-in logs, sampling/ID records, storage condition trends, reconciliation sheets for HD handling, controlled access logs.

5) Personnel Qualification & Gowning (Competency → Authorization)

Define competency pathways: initial training (theory of asepsis/HD safety), gowning qualification, media-fill/aseptic process simulation, glove fingertip testing, and ongoing re-qualification at defined intervals. Use risk-based curricula mapped to roles (e.g., IV production, chemotherapy aseptic prep, nonsterile batch making, HD receipt). Enforce gowning sequences per room class; for HDs, add appropriate respiratory/dermal protection.

• Acceptance: All aseptic operators pass initial and periodic media-fills and fingertip plates within limits; gowning observations documented; failures drive retraining before release to production.
• Evidence: Skills matrix, training records, gowning observation checklists, microbiological qualification results, corrective training logs.

6) Nonsterile Compounding (USP <795> / EU/UK Equivalents)

Use master formulation records (MFRs) for each preparation: formula, calculations, equipment, steps, packaging, labeling, Beyond-Use Date (BUD), and acceptance criteria. For batch preparations, use batch worksheets with reconciliation. Control mixing and homogeneity (e.g., geometric dilution, validated mixing times), and verify potency/identity where risk warrants (e.g., pediatric dose slurries).

• Acceptance: Weigh/measure accuracy within limits; visual/texture checks pass; potency verification (as defined); labels include ingredients, strength, BUD, storage, cautions, patient instructions.
• Evidence: Executed worksheets, QC checks, balance logs, label proofs, deviation/CAPA where criteria fail.

7) Sterile Compounding (USP <797> / Hospital Aseptic Units)

Operate to a risk-tiered model (immediate-use vs categorized CSPs), with aseptic technique, first-air protection, and sterility assurance controls. Validate aseptic processes via media fills representative of worst-case manipulations and durations; control filter integrity (pre/post bubble point) for sterilizing filtration; specify pressure differentials and dynamic EM during operations.

• Acceptance: Media fills pass with zero growth; glove fingertip sampling ≤ limits; viable air/surface counts within alert/action; filter integrity passes; container closure integrity strategy defined where applicable.
• Evidence: Media fill protocols/reports, filter integrity logs, EM results and trends, intervention/deviation records, line clearance and aseptic start-up checklists.

8) Hazardous Drugs (USP <800>) — Containment & Safety

Implement a hazardous drug (HD) list (e.g., NIOSH-based) and conduct risk assessments for non-antineoplastic HDs and dosage forms. Use negative pressure C-SEC for HD compounding; closed-system transfer devices (CSTDs) where mandated or risk-justified. Apply PPE matrices for receiving, compounding, transport, administration support, and spill response; segregate waste streams.

• Acceptance: Room pressures verified negative; HD residues minimized by surface wipe sampling (if program adopted); spill drills performed; transport containers labeled and secure.
• Evidence: HD risk assessments, CSTD verification, wipe sampling results, spill logs, training & medical surveillance records where applicable.

9) Environmental Monitoring (EM): Viable & Non-Viable

Design an EM program tied to risk and room class: non-viable particles (at rest/operational), viable air (active/passive), surfaces (contact plates/swabs), and personnel monitoring (fingertips/gown). Define alert/action limits, sampling maps (first-air/critical zones), and response rules (clean/reculture/hold/investigate).

• Acceptance: Initial qualification complete; ongoing EM within limits; action excursions investigated with CAPA; trends reviewed at defined intervals (e.g., monthly/quarterly).
• Evidence: EM plan & maps, raw results, trend charts, excursion investigations, disinfectant rotation records.

10) Beyond-Use Dating (BUD) & Stability Rationale

Assign BUDs per applicable standards (sterile/nonsterile categories, sterility risk, preservative systems, compatibility, and storage). Where extended BUDs are needed (e.g., centralized ready-to-administer doses), base on stability-indicating data, sterility assurance evidence, and packaging/CCI performance. For UK/EU aseptic units, align with national QA frameworks and product-specific stability monographs where available.

Preparation Type	Key Determinants	Evidence Considerations
Nonsterile aqueous	Microbial risk, preservative	Micro limits/preservative efficacy (if applicable), chemical stability
Nonsterile non-aqueous	Oxidation/hydrolysis risk	Chemical stability data, container compatibility
Sterile low-risk manipulations	ISO class, process duration	Media fill representativeness, EM trends, filter integrity/aseptic controls
HD sterile CSPs	Containment, toxicity	Additional handling controls, wipe sampling (if used), packaging robustness

11) Packaging, Labeling & Distribution (Ward/Clinic Transport)

Use containers that maintain sterility/quality and protect from light/temperature. Labels must include ingredients, concentrations, patient identifiers (if patient-specific), preparer/checker, BUD, storage, auxiliary warnings (e.g., cytotoxic), and administration instructions. Validate transport (time/temperature), especially for cold-chain doses and fragile CSPs; document handover to wards/clinics with tamper-evident seals where appropriate.

• Acceptance: Labels accurate and legible; transport conditions maintained; chain-of-custody records complete.
• Evidence: Label proofs, distribution logs, temperature logger reports, return/rework SOPs for delayed administrations.

12) Documentation & Data Integrity (Paper/Electronic)

Design master formulation/compounding records with clear steps, calculations, checks, and sign-offs. Keep records ALCOA+ compliant; for electronic systems (compounding software, eMAR, QMS), implement role-based access, audit trails, time synchronization, backup & restore testing, and periodic audit trail review with defined filters (create/modify/delete, admin actions, failed logins, configuration changes).

13) Deviation, Investigation, CAPA & Change Control

Capture incidents: EM excursions, aseptic breaches, labeling errors, transport temperature alarms, dose mis-preps, HD spills. Investigate with sharp problem statements and evidence packs (data, photos, device logs). Prefer system fixes (design/engineering/training with effectiveness checks) over reminders. Control changes (formula, PEC setpoints, disinfectants, labels, suppliers) with impact assessment on sterility, safety, and BUD.

• Acceptance: Root cause evidence-based; CAPA includes measurable effectiveness checks (e.g., “0 label mix-ups in 10,000 doses; reconciliation variance ≤ X% for 60 days”).
• Evidence: Investigation/CAPA files, EC results, change control packs with verification/validation results.

14) Quality Review & Management Oversight

Run a periodic Quality Review summarizing EM trends, process failures, complaints/near-misses, training gaps, BUD/stability issues, changes, and CAPA performance. Assign decisions with owners and deadlines; perform read-across where risks are systemic (e.g., across satellite sites).

15) Risk-to-Criteria Cheat Sheet (Quick Design Aid)

Risk	Control	Acceptance Criteria	Evidence to Show
Aseptic breach during long manipulations	Media fills, first-air discipline, interventions SOP	Media fills pass; interventions documented/qualified	Media fill reports; intervention logs; EM trends
Labeling/ID error	Independent check, barcode where available, reconciliation	0 mix-ups; variance within tolerance	Check logs; rejects; deviation/CAPA
HD exposure	C-SEC negative pressure; PPE; CSTDs; spill kits	Room ΔP within limits; spill drills successful	ΔP logs; wipe tests (if used); drill records
Transport temperature excursion	Validated shipper; time/temp control; SOP for delays	Excursions assessed; product disposition justified	Logger data; excursion forms; QA decisions
Documentation gaps	Controlled forms; audit trails; periodic review	Records complete/legible; ATR on schedule	ATR logs; controlled templates; restore tests

16) Methods, Tools & Templates (Ready to Use)

• Master Formulation Record (MFR) Template: formula & calculations, equipment/settings, steps, in-process checks, acceptance criteria, packaging/labeling, BUD, references.
• Aseptic Start-Up Checklist: line clearance, PEC leak/velocity checks, disinfectant lot/expiry, component status, gowning verification, EM set-up.
• EM Plan & Map: locations by risk; alert/action limits; sampling cadence; investigation triggers; trending format.
• HD Risk Assessment Form: drug/formulation, task, exposure route, controls (CSTD/PPE/room class), residual risk & monitoring.
• Transport Validation Pack: lane mapping, worst-case loads, hold times, acceptance criteria, seasonal re-verification cadence.

17) Case Studies & Pitfalls

Case 1 — Rising fingertip failures. New staff show repeated fingertip growth. Fix: targeted retraining, donning/doffing observation, glove disinfection frequency revision. EC: three cycles with pass rates ≥ target; no EM action excursions.

Case 2 — Label mis-match on ward. Strength mismatch identified pre-administration. Fix: barcode check at release, independent calculation verification, label layout redesign. EC: 0 label errors over 8 weeks; reconciliation variance stable.

Case 3 — HD wipe positives. Residues detected on worktops. Fix: CSTD adoption; disinfection agent rotation; staff refresher; change cleaning dwell time. EC: next two quarters below internal threshold.

Case 4 — Transport delays. Cold-chain CSPs delayed by ward closures. Fix: contingency SOP with “return to pharmacy” flow and conditional reuse criteria; extra logger in shuttle. EC: 100% timely disposition; no unassessed use.

18) FAQs

• Do hospital pharmacies need “full GMP”? For in-house compounding for your patients, follow pharmacy/compounding standards (USP/NHS QA). If you manufacture for wider supply or as “Specials,” expect GMP-like controls and, in the UK, MHRA licensing.
• How often should media fills be done? At initial qualification and at defined intervals (e.g., semi-annual for each operator/process), and after significant changes or failures.
• Can BUDs be extended? Only with robust evidence (stability-indicating data, sterility assurance, CCI/packaging). Otherwise, adhere to compendial limits.
• Is wipe sampling mandatory for HDs? Not universally, but it’s a useful verification of housekeeping and containment programs; follow your jurisdiction’s guidance and risk assessments.
• Are electronic compounding records acceptable? Yes, if they meet ALCOA+ and Part 11-equivalent controls (unique IDs, e-sig, ATR, backups, periodic review).

References & Further Reading

• USP <795> Nonsterile Compounding; USP <797> Sterile Compounding; USP <800> Hazardous Drugs
• NIOSH Lists & Guidance on Hazardous Drugs
• EU/UK Hospital Aseptic Services Guidance (NHS QA/Technical Services), national inspectorate publications
• PIC/S Guides to GMP and aide-mémoires for inspectorates
• ICH Q9(R1) Quality Risk Management; ICH Q10 Pharmaceutical Quality System

{
“@context”:”https://schema.org”,
“@type”:[“TechArticle”,”FAQPage”],
“headline”:”GMP for Pharmacies & Hospital Pharmacy Settings — Step-by-Step, Inspection-Ready Guide”,
“description”:”Implementation guide for US/EU/UK pharmacy GMP: USP //, hospital aseptic services, facilities/HVAC, sterile and nonsterile compounding, hazardous drugs, EM, BUDs, documentation, DI, deviation/CAPA/change, and inspection readiness.”,
“dateModified”:”2025-11-14″,
“author”:{“@type”:”Organization”,”name”:”PharmaGMP.com”},
“publisher”:{“@type”:”Organization”,”name”:”PharmaGMP.com”},
“mainEntity”:[
{“@type”:”Question”,”name”:”Do hospital pharmacies need “full GMP”?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”In-house compounding follows pharmacy/compounding standards (USP/NHS QA). Wider supply or “Specials” manufacture requires GMP-like controls and, in the UK, MHRA licensing.”}},
{“@type”:”Question”,”name”:”How often should media fills be done?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”At initial qualification, at defined intervals (e.g., semi-annual per operator/process), and after significant changes or failures.”}},
{“@type”:”Question”,”name”:”Can BUDs be extended?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Only with robust evidence: stability-indicating data, sterility assurance and packaging/CCI support; otherwise adhere to compendial limits.”}},
{“@type”:”Question”,”name”:”Is wipe sampling mandatory for HDs?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Not universally required; it verifies containment/cleaning effectiveness and should follow jurisdictional guidance and your risk assessment.”}},
{“@type”:”Question”,”name”:”Are electronic compounding records acceptable?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Yes, if ALCOA+ is maintained and Part 11-equivalent controls (unique IDs, e-signatures, audit trails, backups, reviews) are implemented.”}}
],
“breadcrumb”:{
“@type”:”BreadcrumbList”,
“itemListElement”:[
{“@type”:”ListItem”,”position”:1,”name”:”GMP for Pharmacies & Hospital Pharmacy Settings”,”item”:”https://www.pharmagmp.com/pharmacy-gmp-hospital-compounding-pillar/”},
{“@type”:”ListItem”,”position”:2,”name”:”Category Pillar”,”item”:”https://www.pharmagmp.com/pharmacy-gmp-hospital-compounding-pillar/”}
]
}
}